Table 2.

Open-Ended Responses to Preference Reasons

Would (n = 79)	n (%)	Would not (n = 13)	n (%)
Long-acting injectable
Would not have to take a daily pill	34 (43)	Does not like needles	6 (46)
Convenience	24 (30.4)	Safety or effectiveness	3 (23.1)
Timing or dosage frequency	9 (11.4)	Logistical difficulty	2 (15.4)
Ease of mind	9 (11.4)	Inconvenience	2 (15.4)
Safety or effectiveness	3 (3.8)

Would (n = 14)	n (%)	Would not (n = 73)	n (%)
Rectal microbicide
Convenience	5 (35.7)	Safety or effectiveness	22 (30.1)
Timing or dosage frequency	3 (21.4)	Inconvenience	16 (21.9)
Perceptions of fewer side effects	2 (14.3)	Logistical difficulty	9 (12.3)
Would not have to take a daily pill	1 (7.1)	Sexual positioning	9 (12.3)
Logistical ease	1 (7.1)	Physical or psychological discomfort	5 (6.9)
Initial positive reaction	1 (7.1)	Initial negative reaction	4 (5.5)
Sexual pleasure	1 (7.1)	Timing or dosage frequency	4 (5.5)
		Sexual pleasure	3 (4.1)
		Concerns about side effects	1 (1.4)

Would (n = 29)	n (%)	Would not (n = 61)	n (%)
Antibody infusion
Convenience	13 (44.8)	Timing or dosage frequency	16 (26.2)
Timing or dosage frequency	7 (24.1)	Does not like needles	10 (16.4)
Would not have to take a daily pill	7 (24.1)	Physical or psychological discomfort	8 (13.1)
Logistical ease	1 (3.5)	Inconvenience	8 (13.1)
Safety or effectiveness	1 (3.5)	Logistical difficulty	7 (11.5)
		Initial negative reaction	5 (8.2)
		Safety or effectiveness	5 (8.2)
		Concerns about side effects	1 (1.6)
		Lack of information	1 (1.6)

Would (n = 72)	n (%)	Would not (n = 21)	n (%)
Subdermal implant
Convenience	35 (48.6)	Physical or psychological discomfort	10 (47.6)
Timing or dosage frequency	18 (26.4)	Lack of information	4 (19)
Would not have to take a daily pill	10 (13.9)	Safety or effectiveness	3 (14.3)
Ease of mind	3 (4.1)	Initial negative reaction	2 (9.5)
Logistical ease	2 (2.8)	Inconvenience	1 (4.8)
Initial positive reaction	2 (2.8)	Concerns about side effects	1 (4.8)
Logistical difficulty	1 (1.4)